SUSVIMO™ Ranibizumab 10 mg / mL Injection .01 mL

Name: Vascular endothelial growth factor (VEGF-A) inhibitor
Brand: SUSVIMO™

SUSVIMO, VL 100MG/ML (1/CT)

McKesson #

1284268

Manufacturer #

50242007812

Brand

SUSVIMO™

Manufacturer

Genentech USA Inc

Country of Origin

Unknown

Application

Vascular endothelial growth factor (VEGF-A) inhibitor

Buy American Act (BAA) Compliant

Container Type

Single-Dose Vial

Dosage Form

Injection

Generic Drug Name

Ranibizumab

NDC Number

50242007812

Product Dating

McKesson Acceptable Dating: we will ship >= 180 days

Storage Requirements

Requires Refrigeration

Strength

10 mg / mL

Trade Agreement Act (TAA) Compliant

Type

Intravitreal

UNSPSC Code

51111761

Volume

.01 mL

SUSVIMO™ (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant
SUSVIMO (ranibizumab injection), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor
Each SUSVIMO (ranibizumab injection) carton contains one SUSVIMO (ranibizumab injection) 100 mg/mL that is clear to slightly opalescent, colorless to slightly brownish solution in a single-dose glass vial